Genitourinary Cancer

Top Story

Nivolumab-ipilimumab combination improves response rate in renal cell carcinoma

August 16, 2017

A phase 3 trial designed to compare nivolumab plus ipilimumab with sunitinib monotherapy for first-line treatment of intermediate- or poor-risk patients with renal cell carcinoma met its coprimary endpoint of objective response rate.

Results showed a trend toward improved PFS — the trial’s other coprimary endpoint — with the combination, but the difference did not reach statistical significance.

In the Journals

Elevated MI, stroke risk common with newly diagnosed cancer

August 15, 2017
Patients with newly diagnosed cancer have elevated risk for MI and stroke, particularly in the first 6 months after diagnosis, according to data published in the…
In the Journals Plus

Older patients with cancer may burden caregivers by overestimating physical abilities

August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
In the Journals Plus

Out-of-pocket cancer expenses often exceed patients’ expectations

August 10, 2017
One-third of insured patients with cancer had out-of-pocket costs that exceeded their expectations, according to study results. Underinsured patients faced the greatest…
More Headlines »
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video
Meeting News Coverage

VIDEO: Long-term nivolumab therapy produces ‘exciting’ results in kidney cancer

September 9, 2016
More »
Resource Centers

CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Advertisement
Advertisement